1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Allos Therapeutics

Anonymous board for Allos Therapeutics

Sort By:
Title
Replies Views ↓
Last Message
  1. Anonymous
    Replies:
    40
    Views:
    35,277
  2. Anonymous
    Replies:
    32
    Views:
    14,080
  3. Anonymous
    Replies:
    28
    Views:
    9,896
  4. Anonymous
    Replies:
    52
    Views:
    8,354
  5. Anonymous
    Replies:
    20
    Views:
    7,677
  6. Anonymous
    Replies:
    56
    Views:
    7,250
  7. Anonymous
    Replies:
    49
    Views:
    7,090
  8. Anonymous
    Replies:
    15
    Views:
    6,205
  9. JS does not have Heartitude
    Replies:
    14
    Views:
    4,902
  10. Anonymous
    Replies:
    9
    Views:
    4,812
  11. Anonymous
    Replies:
    10
    Views:
    4,799
  12. Anonymous
    Replies:
    39
    Views:
    4,690
  13. Anonymous
    Replies:
    25
    Views:
    4,398
  14. Anonymous
    Replies:
    29
    Views:
    4,178
  15. Anonymous
    Replies:
    18
    Views:
    3,956
  16. Anonymous
    Replies:
    4
    Views:
    3,950
  17. Anonymous
    Replies:
    15
    Views:
    3,825
  18. Anonymous
    Replies:
    7
    Views:
    3,813
  19. Anonymous
    Replies:
    14
    Views:
    3,799
  20. Anonymous
    Replies:
    2
    Views:
    3,762

Thread Display Options

Loading...